Peroxidative metabolism of arachidonic acid in the course of Lyme arthritis

Anna Moniuszko 2  ,  
Department of Analytical Chemistry, Medical University of Bialystok, Poland
Department of Infectious Diseases and Neuroinfection, Medical University of Bialystok, Poland
Ann Agric Environ Med 2015;22(3):433–437
The objective of the study was measurement of serum arachidonic acid level as well as the product of its peroxidation – 8-isoPGF, and the activity of phospholipase A2 and PAF-acetylhydrolase that participate in releasing 8-isoPGF from glycerol skeleton, and the potential designation of their role in the pathomechanism of Lyme disease (LD).

Material and Methods:
Changes in the phospholipid arachidonic acid level and the level of 8-isoPGF were determined in the plasma and urine of patients with LA (n=57) and of healthy controls (n=41). The activity of phospholipase A2 and PAF acetylhydrolase were assayed. All examined parameters were also measured in the plasma of some LA patients (n=13) after antibiotics treatment.

An almost 3-fold higher level of the total plasma 8-isoPGF was observed in LA patients compared to the controls, while in the urine it increased over 5-fold. The plasma PLA2 activity was more than 3-fold higher in LA patients than in the healthy subjects, while PAF acetylhydrolase activity was observed to be modestly, but not significantly lower. The total 8-isoPGF level in the plasma and urine of LA patients was significantly lower after antibiotics treatment. The plasma activity of PAF-AH in the LA patients was increased, while the cPLA2 activity decreased after antibiotics treatment.

It may be suggested that in the course of LA, the level of binding 8-isoPGF is significantly enhanced, and it may also be suggested that uncontrolled changes in the lipid status of some patients may make their Lyme arthritis unresponsive to antibiotics.

Anna Moniuszko   
Department of Infectious Diseases and Neuroinfection, Medical University of Bialystok, Poland
1. Kean IR, Irvine KL. Lyme disease: aetiopathogenesis, factors for disease development and control. Inflammopharmacology 2013; 21(2):101–11.
2. Nardelli DT, Callister SM, Schell RF. Lyme Arthritis: Current Concepts and a Change in Paradigm. Clin. Vaccine Immunol. 2008; 15: 21–34.
3. Guerau-de-Arellano M, Alroy J, Huber BT. Beta2 integrins control the severity of murine Lyme carditis. Infect Immun. 2005; 73: 3242–3250.
4. Suhonen J, Hartiala K, Tuominen-Gustafsson H, Viljanen MK. Borrelia burgdorferi-induced oxidative burst, calcium mobilization, and phagocytosis of human neutrophils are complement dependent. J Infect Dis. 2000; 181: 195–202.
5. Pancewicz SA, Skrzydlewska E, Hermanowska-Szpakowicz T, Zajkowska JM, Kondrusik M. Role of reactive oxygen species (ROS) in patients with erythema migrans, an early manifestation of Lyme borreliosis. Med Sci Monit. 2001; 7: 1230–1235.
6. Łuczaj W, Moniuszko A, Rusak M, Pancewicz S, Zajkowska J, Skrzydlewska E. Lipid peroxidation products as potential bioindicators of Lyme arthritis. Eur J Clin Microbiol Infect Dis. 2011; 30: 415–422.
7. Morrow JD, Chen Y, Brame CJ, Yang J, Sanchez SC, Xu J, Zackert WE, et al. The Isoprostanes: unique prostaglandin – like products of free radical initiated lipid peroxidation. Drug Metab Rev. 1999; 31: 117–139.
8. Seet RC, Lee CY, Lim EC, Tan JJ, Quek AM, Chong WL, et al. Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free Radic Biol Med. 2010; 48: 560–566.
9. Milne GL, Yin H, Morrow JD. Human Biochemistry of the Isoprostane Pathway. J Biol Chem. 2008; 283: 15533–15537.
10. Coolen SA, van Buuren B, Duchateau G, Upritchard J, Verhagen H. Kinetics of biomarkers: biological and technical validity of isoprostanes in plasma. Amino Acids. 2005; 29: 429–436.
11. Li H, Lawson JA, Reilly M, Adiyaman M, Hwang S-W, Rokach J, FitzGerald GA. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine. Proc Natl Acad Sci USA. 1999; 96: 13381–13386.
12. Raatz SK, Bibus D, Thomas W, Kris-Etherton P. Total fat intake modifies plasma fatty acid composition in humans. J Nutr. 2001; 131: 231–234.
13. Bradford A, Atkinson J, Fuller N, Rand RP. The effect of vitamin E on the structure of membrane lipid assemblies. J Lipid Res. 2003; 44: 1940–1945.
14. Blaho VA, Buczynski MW, Brown CR, Dennis EA. Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis. J Biol Chem. 2009; 284: 21599–21612.
15. Blaho VA, Mitchell WJ, Brown CR. Arthritis Develops but Fails to Resolve During Inhibition of Cyclooxygenase 2 in a Murine Model of Lyme Disease. Arthritis Rheum. 2008; 58: 1485–1495.
16. Roberts LJ2nd, Fessel JP. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids. 2004; 128: 173–186.
17. Halliwell B, Lee CY. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Antioxid Redox Signal. 2010; 13: 145–156.
18. Halliwell B, Gutteridge JM. Free Radicals in Biology and Medicine. 3rd ed. New York, US, Oxford University Press, Inc., 1999.
19. Katsuki H, Okuda S. Arachidonic acid as a neurotoxic and neurotrophic substance. Prog Neurobiol. 1995; 46: 607–36.
20. Van den Berg JJM, Op den Kamp JAF, Lubin BH Kuypers FA. Conformational changes in oxidized phospholipids and their preferential hydrolysis by phospholipase A2: a monolayer study. Biochemistry. 1993; 32: 4962–4967.
21. McIntyre TM, Prescott SM, Stafforini DM. The emerging roles of PAF acetylhydrolase. J Lipid Res. 2009; 50: 255–259.
22. Ito S, Noguchi E, Shibasaki M, Yamakawa-Kobayashi K, Watanabe H, Arinami T. Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma. J Hum Genet. 2002; 47: 99–101.
23. Varga J, Yufit T, Hitraya E, Brown RR. Control of extracellular matrix degradation by interferon-gamma. The tryptophan connection. Adv Exp Med Biol. 1996; 398: 143–148.
24. Bockenstedt LK, Gonzalez DG, Haberman AM, Belperron AA. Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest. 2012; 122: 2652–2660.
25. Li X, McHugh GA, Damle N, Sikand VK, Glickstein L, Steere AC. Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum. 2011; 63: 2238–2247.